Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Biomarin Pharmaceutical Inc (BMRN)  
$88.63 1.44 (1.6%) as of 4:30 Fri 4/19


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 188,370,000
Market Cap: 16.70(B)
Last Volume: 1,778,607 Avg Vol: 1,398,026
52 Week Range: $76.22 - $99
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Drug Manufacturers - Other

Member Indexes:
    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  811
Guru Rank Value     : 0.9
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 3,625
Total Buy Value $0 $0 $0 $314,469
Total People Bought 0 0 0 1
Total Buy Transactions 0 0 0 1
Total Shares Sold 156,079 229,843 273,203 611,547
Total Sell Value $13,472,349 $20,340,408 $24,241,430 $58,103,504
Total People Sold 5 5 6 7
Total Sell Transactions 13 19 25 55
End Date 2024-02-15 2023-11-14 2023-05-16 2022-05-16

   
Records found: 2560
  Page 1 of 103  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Bienaime Jean Jacques Director   –       •      –    2024-05-10 4 AS $81.14 $1,622,800 D/D (20,000) 474,994     -
   Bienaime Jean Jacques Director   –       •      –    2024-05-10 4 OE $63.10 $1,262,000 D/D 20,000 494,994     -
   Bienaime Jean Jacques Director   –       •      –    2024-05-09 4 AS $81.62 $1,632,400 D/D (20,000) 474,994     -
   Bienaime Jean Jacques Director   –       •      –    2024-05-09 4 OE $63.10 $1,262,000 D/D 20,000 494,994     -
   Guyer Charles Greg EVP, Chief Technical Officer   •       –      –    2024-05-03 4 D $82.44 $366,034 D/D (4,440) 74,132     -
   Ajer Jeffrey Robert EVP, Chief Commercial Officer   •       –      –    2024-05-02 4 AS $82.91 $414,550 D/D (5,000) 66,767     -
   Davis George Eric EVP, Chief Legal Officer   •       –      –    2024-05-02 4 AS $85.01 $157,269 D/D (1,850) 56,157     -
   Davis George Eric EVP, Chief Legal Officer   •       –      –    2024-05-02 4 OE $63.10 $116,735 D/D 1,850 58,007     -
   Guyer Charles Greg EVP, Chief Technical Officer   •       –      –    2024-04-30 4 A $68.65 $16,818 D/D 245 78,572     -
   Ajer Jeffrey Robert EVP, Chief Commercial Officer   •       –      –    2024-04-30 4 A $68.65 $20,594 D/D 300 71,767     -
   Davis George Eric EVP, Chief Legal Officer   •       –      –    2024-04-30 4 A $68.65 $20,662 D/D 301 56,157     -
   Bienaime Jean Jacques Director   –       •      –    2024-04-12 4 AS $91.26 $1,825,200 D/D (20,000) 474,994     -
   Bienaime Jean Jacques Director   –       •      –    2024-04-12 4 OE $63.10 $1,262,000 D/D 20,000 494,994     -
   Bienaime Jean Jacques Director   –       •      –    2024-04-11 4 AS $90.99 $1,819,800 D/D (20,000) 474,994     -
   Bienaime Jean Jacques Director   –       •      –    2024-04-11 4 OE $63.10 $1,262,000 D/D 20,000 494,994     -
   Burkhart Erin GVP, Chief Accounting Officer   •       –      –    2024-04-10 4 AS $90.00 $205,740 D/D (2,286) 16,156     -
   Davis George Eric EVP, Chief Legal Officer   •       –      –    2024-03-28 4 AS $88.34 $2,173,341 D/D (24,602) 55,856     -
   Slamon Dennis Director   –       •      –    2024-03-18 4 D $83.81 $797,033 D/D (9,510) 31,299     -
   Slamon Dennis Director   –       •      –    2024-03-18 4 OE $79.70 $797,000 D/D 10,000 40,809     -
   Burkhart Erin GVP, Chief Accounting Officer   •       –      –    2024-03-18 4 D $83.87 $31,200 D/D (372) 18,442     -
   Fuchs Henry J President, Worldwide R&D   •       –      –    2024-03-15 4 D $83.87 $2,808,387 D/D (33,485) 196,872     -
   Fuchs Henry J President, Worldwide R&D   •       –      –    2024-03-15 4 A $0.00 $0 D/D 18,240 230,357     -
   Burkhart Erin GVP, Chief Accounting Officer   •       –      –    2024-03-15 4 A $0.00 $0 D/D 4,720 18,814     -
   Hardy Alexander Chief Executive Officer   •       •      –    2024-03-15 4 A $0.00 $0 D/D 32,780 148,151     -
   Davis George Eric EVP, Chief Legal Officer   •       –      –    2024-03-15 4 D $83.87 $1,819,895 D/D (21,699) 80,458     -
  2560 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 1 of 103
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us